AML

Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Mulitcenter 2 part study to access the safety, tolerability, Pharmaconetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study: Drug used in study:
  • MDS not responding to hypomethylation therapy or recurrence after initial response; AML with relapsed following CR1; HLA-a2.01 positive.

HR 57

A Phase 1/2 Dose finding study to evaluate the safety, feasibility, and activity or BPX-701, a controllable Prame T-Cell receptor therapy, in HLA-A2 + subjects with relapsed Acute Myeloid Leukemia, previously treated Myelodysplastic Syndrome, or Metastatic Uveal Melanoma.

Criteria to qualify for study: Drug used in study:
  • Relapsed or Refractory

Hemref 43 TTI-621 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relpased of Refractory Hematologic Malignancies Phase 1a Escalation / Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis / ANC > 1.5 / PLT > 75 / HGB > 10 in absence of transfusion and growth factors for at least 28 days /ECOG 0,1 or 2 /

Criteria to qualify for study: Drug used in study:
  • R/R, AML/MM/DLBCL

Hemeref51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML or previously treated and previous treated MDS
  • Patients need to be tested for TP53 status using NGS
  • Patients must have recovered from the previous therapy to Grade 1 or base line of significant toxicities and 5half-lives or 4 weeks

HR 49 ALRN-6924-1-02

A phase 1/1b open label study to determine the safety and tolerability of ALRN-6924 alone and in combination with Cyterabine (Ara-C) in patients with Relapsed/Refractory Acute Myeloid Leukemia of Advanced Myelodysplastic Syndrome with Wild-Type TP53.

Criteria to qualify for study: Drug used in study:
  • First line treatment
  • Low blast count

MDS 21

Phase 3, Randomized, Controlled, Open label, Clinical Study of Pevonedistat Plus Azacitidine versus single agent Azacitidine as First-Line treatment for patients with higher risk Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia, of Low Blast Acute Myelogenous Leukemia.